Covid-19 Vaccine Candidate from Clover Biopharmaceuticals showed 79% protective efficacy against Delta variant in global Phase 2/3 Clinical Trials.

Sep.24 2021

Clover Biopharmaceuticals, working with CEPI (Coalition for Epidemic Preparedness Innovations), announced recently, the recombinant protein COVID-19 candidate vaccine SCB-2019 (CpG 1018/aluminum adjuvant) used in combination with Clover’s adjuvant met the primary and secondary endpoints of protective efficacy in the global Phase 2/3 clinical trial ( "SPECTRA").  All (100%) of the new coronavirus strains observed in the analysis of the test results were variants, indicating the protective efficacy of the vaccine against the mutant strains. The SCB-2019 (CpG 1018/aluminum adjuvant) has 79% protective efficacy against pneumonia caused by the Delta variant, which is currently the major global epidemic strain. 

Clover’s COVID-19 candidate vaccine is one of the first COVID-19 vaccines to demonstrate significant protective efficacy against the Delta variant in a randomized, double-blind clinical trial.  

SAFE Pharmaceutical Technologies Co., Ltd., as Clover’s strategic vaccine development partner,   undertook part of the preclinical evaluation study of Clover’s COVID-19 candidate vaccine.

In addition, SAFE also conducted numerous preclinical evaluations of COVID-19 emergency prevention and control drugs, ranging from inactivated vaccines, mRNA vaccines, recombinant protein vaccines, to novel vector vaccines and antibodies, to name a few.